Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.71 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | TYMS | P04818 | 2/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152753 | 0.90 | ADRB1 (0.64) | ADRB1DNMT1POLBNT5EENPP1 | |
| SCHEMBL3075710 | 0.90 | ADRB1 (0.64) | ADRB1DNMT1POLBNT5EENPP1 | |
| SCHEMBL19283452 | 0.87 | DNMT1 (0.76) | ADRB1DNMT1POLBNT5EENPP1 | |
| Decitabine SCHEMBL3396534 | 0.86 | DNMT1 (0.91) | ADRB1DNMT1POLBNT5E | |
| SCHEMBL16366026 | 0.86 | DNMT1 (0.74) | ADRB1DNMT1POLBNT5EENPP1 | |
| Decitabine SCHEMBL459668 | 0.86 | DNMT1 (0.91) | ADRB1DNMT1POLBNT5E | |
| SCHEMBL10064225 | 0.86 | DNMT1 (0.74) | ADRB1DNMT1POLBNT5EENPP1 | |
| SCHEMBL5076376 | 0.85 | DNMT1 (0.73) | ADRB1DNMT1POLBNT5EENPP1 | |
| SCHEMBL12746576 | 0.85 | DNMT1 (0.66) | ADRB1DNMT1POLBNT5ETYMS | |
| SCHEMBL23152696 | 0.84 | DNMT1 (0.71) | ADRB1DNMT1POLBNT5EENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ADRB1 2147/4885DNMT1 2586/4885POLB 1168/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ADRB1 2147/4885DNMT1 2586/4885POLB 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.